[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
Treatment is initiated when the McDonald criteria for relapsing-remitting multiple sclerosis (RRMS) are fulfilled. High-risk patients with clinically isolated syndrome are followed using magnetic resonance imaging for one year after the first imaging. Interferon-beta or glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. MxA protein is measured 12 and 24 months after initiation of Interferon-beta to evaluate possible development of neutralizing antibodies. If MxA protein may not be detected repeatedly interferon-beta treatment is discontinued. If the disease is active in spite of treatment with first-line IMD, natalizumab may be considered as a second-line therapy. IMD is stopped when the transition to secondary progressive phase has occurred (or upon transition to secondary progressive phase).
Elovaara
Irina
I
Atula
Sari
S
Erälinna
Juha-Pekka
JP
Färkkilä
Markus
M
Pirttilä
Tuula
T
Remes
Anne
A
Ruutiainen
Juhani
J
Varis
Tiina
T
D018450:Disease Progression; D019204:GTP-Binding Proteins / Q000032:analysis; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy; D064547:Myxovirus Resistance Proteins; D010455:Peptides / Q000627:therapeutic use; D011994:Recombinant Proteins; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D007370:Interferon Type I; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D010455:Peptides; D011994:Recombinant Proteins; D000068717:Glatiramer Acetate; D019204:GTP-Binding Proteins